Figure 4.

Effects of n-3 LC-PUFAs vs a control on GGT levels in patients with NAFLD. A random-effects model was used to calculate the pooled estimate of the differences in means and the accompanying 95%CI. Studies were weighted by the inverse of their variance; the area of each symbol is proportional to the weight of the study. The diamond represents the pooled effect. The pooled change from baseline in serum GGT with intake of n-3 LC-PUFAs, corrected for changes from baseline in the control group, is −5.56 IU/L (95%CI, −9.61 to −1.50 IU/L; P=0.007). Using the trim and fill method of Duval and Tweedie,³⁵ 1 study was found to be missing to the right of the mean effect. With this study imputed, the pooled reduction in serum GGT levels with n-3 LC-PUFAs vs a control is −5.16 IU/L (95%CI, −8.92 to −1.40 IU/L). Abbreviations: DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; GGT, γ-glutamyl transferase; HyperL, hyperlipidemia/dyslipidemia; n-3 LC-PUFAs, omega-3 long-chain polyunsaturated fatty acids; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NR, not reported.